In MIBC, both DFS and OS showed a trend toward improvement (Fig. 5 A and B).
← all excerpts
Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma.
1
—
—
In MIBC, both DFS and OS showed a trend toward improvement (Fig. 5 A and B).